Human life has developed in a 1 g environment. So has disease. What if we could change the forces gravity from the equation of disease development, what unique pathways could we discover that have never previously been observed that could be targeted for new therapeutics to cancer?
Dr Johnson is a research fellow within the Mechanisms in Cell Biology and Diseases Research Group and investigates health disease pathogenesis using space-like environments such as simulated microgravity in the field of Space Biology here at UniSA Clinical & Health Sciences, University of South Australia. Space Biology is the scientific study of how conditions during spaceflight, such as microgravity (0 g) or hypergravity (> ... Read more
About me
Human life has developed in a 1 g environment. So has disease. What if we could change the forces gravity from the equation of disease development, what unique pathways could we discover that have never previously been observed that could be targeted for new therapeutics to cancer?
Dr Johnson is a research fellow within the Mechanisms in Cell Biology and Diseases Research Group and investigates health disease pathogenesis using space-like environments such as simulated microgravity in the field of Space Biology here at UniSA Clinical & Health Sciences, University of South Australia. Space Biology is the scientific study of how conditions during spaceflight, such as microgravity (0 g) or hypergravity (> 1 g), and in the extra-terrestrial environment (e.g. ionising radiation), affect living organisms.
Dr Johnson has extensive experience in cell biology, gaining a Ph.D. from investigations into altered endosome and lysosome biogenesis in prostate cancer and has developed sensitive and specific antibodies that detect three new endosome-related biomarkers within these cells that helps pathologists improve diagnostic and prognostic accuracy of prostate cancer.
Using his cell biology experience, Dr Johnson leads a multi-disciplinary team of researchers in developing and using innovative technologies to study human development and disease pathogenesis in space environments. Collaborating with space biology experts across the globe, Dr Johnson, and his team at UniSA, are using altered-gravity environments to rethink conventional biomedical research. They utilise these space environments to help pinpoint cellular changes that induce disease pathogenesis such as cancer and metastatic progression. In turn, this may lead to novel therapies or preventive countermeasures, enhancing the quality of life for patients.
About me
Australian Society for Biochemistry and Molecular Biology
The Australasian Society of Aerospace Medicine
About me
Doctor of Philosophy University of South Australia
Bachelor of Science(Honours) University of Birmingham
Research
Excludes commercial-in-confidence projects.
Diagnostic and prognostic biomarker test for prostate cancer, EnVision Sciences Pty Ltd, 01/01/2017 - 30/10/2018
Altered endosome trafficking in prostate cancer, PCFA Research Program, 01/01/2017 - 31/12/2017
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2023 |
1
|
2023 |
Open access
|
2023 |
Open access
|
2023 |
Open access
3
|
2023 |
Open access
8
3
7
|
2023 |
Open access
2
|
2022 |
Open access
18
13
1
|
2022 |
Open access
6
4
2
|
2022 |
1
45
|
2020 |
Open access
1
1
4
|
2019 |
1
|
2019 |
Open access
4
2
2
|
2018 |
Open access
25
24
3
|
2018 |
Open access
17
1
|
2018 |
Open access
29
6
|
2018 |
Open access
25
21
9
|
2016 |
24
20
4
|
2015 |
Open access
33
33
2
|
2015 |
Open access
32
25
11
|
2014 |
18
13
1
|
2014 |
Open access
29
26
11
|
Research
Details | Registry | Status |
---|---|---|
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
AU | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
EP | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
SG | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
US | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
WO | Filed |
Gibco™ Cell Culture Hero - Webinar March 2019.
External engagement & recognition
Organisation | Country |
---|---|
Aarhus University | DENMARK |
Austin Health | AUSTRALIA |
Children's Hospital Los Angeles | UNITED STATES |
Curtin University | AUSTRALIA |
Deakin University | AUSTRALIA |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
La Trobe University | AUSTRALIA |
Malaghan Institute of Medical Research | NEW ZEALAND |
Monash University | AUSTRALIA |
National Institute of Child Health and Human Development | UNITED STATES |
NIDCR | UNITED STATES |
Queensland University of Technology | AUSTRALIA |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
The Coombe Hospital | IRELAND |
University College Dublin | IRELAND |
University of Adelaide | AUSTRALIA |
University of Bologna | ITALY |
University of British Columbia | CANADA |
University of Dublin | IRELAND |
University of Melbourne | AUSTRALIA |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
AwardThe Freemasons Foundation |
2014 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
111081 - Introducing a new paradigm for specific targeting of ovarian cancer cells with engineered nanoparticles, using G protein-coupled receptors as molecular entry points | Current |
Defining critical changes in lipid metabolism during prostate cancer progression | Current |
Development of monoclonal antibody targeted therapeutics for prostate cancer | Current |
The role of membrane trafficking in prostate cancer metastasis | Current |
The roles of molecular machinery in androgen receptor trafficking and development of prostate cancer | Current |